MiNK Therapeutics, a clinical-stage biopharmaceutical company, recently announced the initiation of a Phase 2 investigator sponsored study for agenT-797 in second line gastroesophageal cancer. Led by Dr. Yelena Janjigian at the Memorial Sloan Kettering Cancer Center, this study aims to build upon the remarkable findings from MiNK’s previous clinical trial, demonstrating the potential of agenT-797 in overcoming resistance to immune checkpoint inhibitors (ICIs) in patients with chemotherapy and anti-PD-1 refractory gastric cancer.
AgenT-797: A Potential Game-Changer:In a case report published in Oncogene, MiNK Therapeutics heralds the efficacy of agenT-797 in their phase 1/2 study involving patients with advanced solid tumors. This groundbreaking research showcases how a single infusion of agenT-797 resulted in a durable confirmed partial response in gastric cancer refractory to anti-PD1 therapy. Consequently, it highlights the unique potential of invariant natural killer T (iNKT) cells in successfully bypassing the resistance mechanism of ICIs.
Overcoming Immune Checkpoint Inhibitor Resistance:The use of ICIs, such as anti-PD1 therapies, has revolutionized cancer treatment by enhancing the immune system’s ability to recognize and destroy cancer cells. However, some patients develop resistance to these therapies, limiting their efficacy. MiNK’s agenT-797 offers an innovative approach to overcome this resistance, which is particularly promising for patients with refractory gastric cancer.
Combining MiNKs Allogeneic INKT Cell Therapy with Agenus Botensilimab and Balstilimab:The Phase 2 trial led by Dr. Yelena Janjigian incorporates the combination of MiNKs allogeneic iNKT cell therapy (agenT-797) with Agenus’ Botensilimab and Balstilimab. This novel combination aims to further enhance the immunotherapeutic response and effectiveness in treating second line gastroesophageal cancer. By targeting different mechanisms involved in cancer proliferation and immune suppression, this combination therapy offers new hope to patients who have previously experienced resistance to ICIs.
Implications and Future Perspectives:The initial results from MiNK’s clinical trials suggest that the combination of agenT-797 with Agenus’ immune checkpoint inhibitors shows great promise in overcoming resistance to anti-PD1 therapy. These findings have significant implications for the management of refractory gastric cancer and other challenging malignancies. If successful, this novel combination therapy may pave the way for improved treatment options for patients facing resistance to ICIs.
Comments